All In Biotech

Drug Trial Radar · NCT03596450

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,278 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,278

Actual

Start

Jul 13, 2018

Primary completion

Jun 9, 2022

Study completion Jun 9, 2023

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jul 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the participant nor the study doctor or study staff will be able to pick which group the participant is in, but the participant will know which study drug the participant has been assigned to. The study doctor will provide the participant with a prescription for the study diabetes medication based on the treatment group the participant is assigned. The participation will last about 2 years.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • SemaglutideDrug

    Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.

  • Standard of careDrug

    Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No)Time frame: At year 1

Locations

181 sites in 2 countries. Site status is shown where the registry gives one.

  • American Clinical Trials

    Buena Park, California

  • Endocrine Specialty Consultant Inc.

    Burbank, California

  • FDRC

    Costa Mesa, California

  • Bay Area Clinical Research

    Dublin, California

  • Providence Medical Foundation

    Fullerton, California

  • SC Clinical Research, Inc.

    Garden Grove, California

  • SCKE Odyssey Medical Group

    Laguna Hills, California

  • New Hope Consulting & Clinical Trials

    Lancaster, California

  • OM Research LLC

    Lancaster, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • West Coast Endocrine, Inc.

    Long Beach, California

  • Pacific Clinical Studies

    Los Alamitos, California

  • Angel City Research

    Los Angeles, California

  • University of Californ LA-UCLA

    Los Angeles, California

  • Patel, Rahul

    Manteca, California

  • Pacific Medical Center

    Milpitas, California

  • Facey Medical Foundation

    Mission Hills, California

  • Monterey Endocrine & Diabetes Institute, Inc

    Monterey, California

  • Do-Eun Lee

    Napa, California

  • Charles Andrews, MD

    Newport Beach, California

  • Hoag Medical Group

    Newport Beach, California

  • Adam B. Sherman D O Professional Corp.

    Oxnard, California

  • Format Medical Research

    Oxnard, California

  • Stanford Univ School of Med

    Palo Alto, California

  • Posada, Juan

    San Jose, California

  • Joselito C Cabaccan, MD

    San Jose, California

  • Care Access Research Santa Clarita

    Santa Clarita, California

  • Premier Medical Center, Inc.

    Toluca Lake, California

  • Adnab Research/Prestige Care Physician

    Torrance, California

  • Altura Centers For Health

    Tulare, California

  • Tariq Javed, MD Inc.

    Visalia, California

  • Endocrinology & Diabetes Specialists

    Walnut Creek, California

  • PIH Health Physicians Endocrinology

    Whittier, California

  • Optumcare Clinical Trials,LLC-Golden

    Colorado Springs, Colorado

  • Delta Waves, Inc.

    Colorado Springs, Colorado

  • University of Colorado Hospital

    Denver, Colorado

  • Denver Endocrinology Diabetes and Thyroid Center

    Englewood, Colorado

  • ProHealth Physicians/OptumCare

    Bristol, Connecticut

  • Western Connecticut Health Network_Danbury

    Danbury, Connecticut

  • Endocrine Associates of Connecticut

    Hamden, Connecticut

Showing 40 of 181 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.